JPS5877879A - Ｃ−β−Ｄ−キシロピラノシド系化合物 - Google Patents
Ｃ−β−Ｄ−キシロピラノシド系化合物Info
- Publication number
- JPS5877879A JPS5877879A JP17577281A JP17577281A JPS5877879A JP S5877879 A JPS5877879 A JP S5877879A JP 17577281 A JP17577281 A JP 17577281A JP 17577281 A JP17577281 A JP 17577281A JP S5877879 A JPS5877879 A JP S5877879A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- beta
- xylopyranoside
- formula
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 24
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 4
- 239000007818 Grignard reagent Substances 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 150000004795 grignard reagents Chemical class 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000003327 cancerostatic effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 11
- -1 n-octyl Chemical group 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 150000008216 xylosides Chemical class 0.000 description 3
- 208000031968 Cadaver Diseases 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 101100397220 Rhodococcus sp. (strain AD45) isoH gene Proteins 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910000464 lead oxide Inorganic materials 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 102220217298 rs1060503025 Human genes 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940089401 xylon Drugs 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17577281A JPS5877879A (ja) | 1981-11-04 | 1981-11-04 | Ｃ−β−Ｄ−キシロピラノシド系化合物 |
| EP84100499A EP0118676B1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| DE8484100499T DE3176465D1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| EP84100498A EP0117413B1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| EP81110216A EP0053827B1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| DE8181110216T DE3172379D1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| DE8484100498T DE3176380D1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| US06/472,786 US4454123A (en) | 1980-12-09 | 1983-03-07 | O-xylopyranoside series compounds and methods of use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17577281A JPS5877879A (ja) | 1981-11-04 | 1981-11-04 | Ｃ−β−Ｄ−キシロピラノシド系化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5877879A true JPS5877879A (ja) | 1983-05-11 |
| JPH0128750B2 JPH0128750B2 (enExample) | 1989-06-05 |
Family
ID=16001986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17577281A Granted JPS5877879A (ja) | 1980-12-09 | 1981-11-04 | Ｃ−β−Ｄ−キシロピラノシド系化合物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5877879A (enExample) |
-
1981
- 1981-11-04 JP JP17577281A patent/JPS5877879A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0128750B2 (enExample) | 1989-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1087052A3 (ru) | Рентгеноконтрастное средство | |
| US4454123A (en) | O-xylopyranoside series compounds and methods of use | |
| FUJITA et al. | Antitumor activity of acylated oridonin | |
| Shimojima et al. | (Studies on AI-77s, microbial products with pharmacological activity) structures and the chemical nature of AI-77s | |
| US4446312A (en) | C-β-D-Xylopyranoside series compounds | |
| US2738350A (en) | 3-oxygenated 17alpha-aza-d-homoandrostenes and n-substituted derivatives thereof | |
| GB1574246A (en) | Prostaglandin derivatives and process for preparing the same | |
| CN116375582A (zh) | 异甜菊醇衍生物及其应用 | |
| US6048523A (en) | Polyester cyclic compounds, their complexes and bonded bodies | |
| EP2130834A1 (en) | Novel sulfonated sugar derivative, and use thereof for medicinal agent | |
| UA61919C2 (uk) | Амінокислотний складний ефір, що містить азол, спосіб його одержання, проміжні сполуки та фармацевтична композиція | |
| JPS59204167A (ja) | ヒドロキノン誘導体およびその製法 | |
| JPH0723367B2 (ja) | オキサビシクロヘプタン誘導体 | |
| US3985798A (en) | 11α-HOMO-PROSTANOIC ACIDS AND ESTERS | |
| JPS5920298A (ja) | 新規トリテルペン配糖体 | |
| US3394150A (en) | Polynitrates of steroidal alcohols | |
| JPWO2011093471A1 (ja) | ネオポンコラノール類の製造方法 | |
| Mirskova et al. | Synthesis and pharmacological activity of tris-(2-hydroxyethyl) ammonium 4-chlorophenylsulfonylacetate (sulfacetamine) | |
| JPS5967287A (ja) | 新規プルセオライド誘導体及びその製造法 | |
| US4461763A (en) | Oximes of 3'"-dehydrocardenolide tridigitoxosides | |
| JPS6067422A (ja) | 脱腫瘍剤 | |
| JPS61501703A (ja) | プナグランジン類及びその薬学的用途 | |
| JPH02300159A (ja) | 新規な２，２，２‐トリフルオロエタンスルホン酸エステル、及びその製造法、並びにそれを有効成分とする抗癌剤 | |
| JPS6341493A (ja) | ガングリオシドｇｍ↓２関連化合物及びその製造方法 | |
| JPH0128750B2 (enExample) |